Statin-induced vulnerable plaque regression after atorvastatin treatment: serial evaluation by 18F-fluorodeoxyglucose positron emission tomography study.
Latest Information Update: 06 Aug 2009
Price :
$35 *
At a glance
- Drugs Atorvastatin (Primary)
- Indications Atherosclerosis; Hyperlipidaemia
- Focus Pharmacodynamics
- 08 Jan 2009 Status changed from not yet recruiting to completed.
- 08 Jan 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 02 Jan 2009 Actual start date (Mar 2007) added as reported by ClinicalTrials.gov.